AVECTAS LIMITED

Avectas Limited is a biotechnology company dedicated to transforming the manufacturing of autologous cell therapies. Its flagship offering, the Solupore® integrated platform, consolidates activation, transduction, expansion, harvest and non-viral editing into a single, closed consumable that delivers an automated, sensor-enabled workflow. By decoupling the consumable from the core controller, Solupore® enables parallel batch processing with satellite rockers, dramatically reducing clean-room footprint, labour input and overall cost of goods while boosting annual throughput up to six-fold.

The platform is built for both research use and GMP-compliant production, featuring inline pH/DO sensing, automated sampling and electronic batch records that meet 21 CFR Part 11 standards. Avectas' consumable-based approach can cut facility investment by as much as 75 % and lower labour-related expenses by up to 40 %, delivering high-quality CAR-T cells that retain a stem-like phenotype, exhibit low exhaustion and demonstrate potent cytotoxicity within a rapid seven-day process.

Supported by an experienced executive team, scientific advisory board and a robust US-based supply chain, Avectas partners with manufacturers and clinicians seeking scalable, cost-effective cell-therapy solutions for patients worldwide.